What You Should Know:
– Senseonics Holdings, Inc., a provider of long-term implantable continuous glucose monitoring (CGM) systems, today announced a strategic partnership with Rimidi. Rimidi offers a comprehensive clinical management platform designed to improve chronic disease management for patients and healthcare providers.
– The collaboration aims to develop the Eversense® Remote Patient Monitoring (RPM) Program, which will integrate seamlessly with existing healthcare workflows.
Improving Diabetes Care Through Remote Monitoring
The Eversense CGM + RPM solution will combine Senseonics’ long-lasting Eversense sensor with Rimidi’s user-friendly clinical management platform. Here’s how this partnership will benefit patients and providers:
- Streamlined Data Integration: Eversense glucose data will be seamlessly integrated with Rimidi’s platform, allowing it to be pushed securely to widely used Electronic Health Record (EHR) systems. This provides healthcare providers with direct access to a patient’s glucose data, eliminating the need for manual data entry.
- Enhanced Patient Engagement: The program aims to improve patient engagement by providing healthcare providers with tools to proactively monitor glucose trends, identify potential issues, and offer personalized guidance on lifestyle and medication adjustments.
- Improved Clinical Decisions: With increased visibility into patient data, healthcare providers can make more informed decisions about treatment plans, potentially leading to better diabetes management and improved clinical outcomes.
- Reduced Healthcare Costs: By enabling proactive care and potentially preventing complications, the Eversense CGM + RPM solution has the potential to reduce overall healthcare costs associated with diabetes management.
Partnership Aligns with Industry Standards
Rimidi’s platform is designed to meet the requirements of Medicare’s reimbursable remote patient monitoring telehealth programs. It also integrates seamlessly with existing EHR systems, ensuring a smooth workflow for healthcare providers.
Phased Rollout and Future Availability
Senseonics, in collaboration with its commercial partner Ascensia Diabetes Care, plans a phased rollout of the Eversense CGM + RPM solution. The program will initially be made available to select population health-based systems in Q3 2024, with a planned future expansion to all healthcare providers and Eversense users.
“We are excited to combine our clinical management platform with Senseonics’ technology. Our platform and its capabilities were designed to leverage the data from medical devices like Eversense CGM to streamline and improve chronic disease management,” said Chief Executive Officer of Rimidi, Lucienne Ide, MD, PhD. “81% of patients with type 2 diabetes do not meet their HbA1c, blood pressure and cholesterol goals, and this partnership represents an exciting opportunity to assist providers in driving improved glucose outcomes for this population.”
